Pharma’s interest in using big data to demonstrate the value of its medicines and efforts to expand services to patients beyond the pill are resulting in more deals between biopharma and non-traditional partners like digital health firms, data management companies and other service providers.
The growing interest in these kinds of alternative deals, generally partnerships and alliances instead of outright M&A, was evident in 2016. This increasing emphasis on alliances with partners outside the...